Device Trial Radar · NCT07645118
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 22, 2026
Primary completion
Dec 2028
Study completion Dec 2030
Sponsor
- Lead sponsor
- Dr. Te VuongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery (TME) to remove rectal cancer.
Conditions
- Locally Advanced Rectal Cancer
Interventions
NivolumabDrug
2 doses of nivolumab 3 mg/kg mg IV every 2 weeks
HDRBETDevice
26 Gy in 4 fractions Administered over Days 1-4 as per institutional standard
Total Mesorectal Excision (TME)Procedure
Targeted to take place 6-8 weeks post completion of HDREBT (maximum 12 weeks)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathologic complete response (pCR)Time frame: This is assessed at the time of total mesorectal excision surgery, occurring approximately 12 weeks after enrollment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jewish General Hospital
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.